NOVEL IMMUNOTOXIN AND IGF THERAPY FOR STRABISMUS

$156,634P51FY2011RRNIH

University Of Washington, Seattle WA

Investigators

Linked publications, trials & patents

Paper 39605643 Paper 38182420 Paper 37995854 Paper 37695892 Paper 37425739 Paper 37098066 Paper 36738735 Paper 35859531 Paper 35759657 Paper 34862189 Paper 34432996 Paper 34424236 Paper 34006588 Paper 33978232 Paper 33914754 Paper 33479371 Paper 32580663 Paper 31567096 Paper 31405926 Paper 30995136 Paper 30948478 Paper 30699004 Paper 30570484 Paper 30367140 Paper 29899029 Paper 29677324 Paper 29607423 Paper 29566355 Paper 29386511 Paper 29358369 Paper 29305531 Paper 28760867 Paper 28743725 Paper 28450831 Paper 28418297 Paper 28343228 Paper 28159911 Paper 28093479 Paper 27852699 Paper 27820875 Paper 27379234 Paper 27314177 Paper 27194333 Paper 27148554 Paper 27148525 Paper 27069950 Paper 26972791 Paper 26715195 Paper 26571270 Paper 26505868 Paper 26455307 Paper 26438271 Paper 26417083 Paper 26284599 Paper 26086366 Paper 26038465 Paper 26038402 Paper 26029716 Paper 25985411 Paper 25922477 Paper 25855693 Paper 25765047 Paper 25690930 Paper 25661183 Paper 25652917 Paper 25649764 Paper 25637856 Paper 25515075 Paper 25461538 Paper 25445192 Paper 25402233 Paper 25392405 Paper 25355068 Paper 25315244 Paper 25280789 Paper 25253473 Paper 25245586 Paper 25123306 Paper 25102089 Paper 25057148 Paper 25036018 Paper 25032212 Paper 24948811 Paper 24862987 Paper 24803409 Patent 8246959 Patent 7449186 Patent 7148006 Patent 6374670 Patent 6326151 Patent 6123915 Patent 6051375 Patent 6030785 Patent 6022542 Patent 6015565 Patent 5925733 Patent 5827670 Patent 5788713 Patent 5670330 Patent 5206345

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The goal of this project is to develop and evaluate novel agents, including growth factors and immunotoxins that could lead to improved treatment options for strabismus. This work is directed at testing the efficacy of growth factors in altering extraocular eye muscle function of non-human primates. The ultimate goal is to be able to apply our results to improve treatment of human strabismus.

View original record on NIH RePORTER →